



## Original Research Article

## To study correlation of HbA1c and macular thickness changes in diabetic patients after phacoemulsification and small incision cataract surgery (SICS)

Avani Soni<sup>1</sup>, Rajni Sethia<sup>1,\*</sup>, Parin Mehta<sup>2</sup>, Zeel Patel<sup>1</sup>, Aneesa Vyas<sup>1</sup>

<sup>1</sup>Dept. of Ophthalmology, SBKS MI & RC, Sumandeep Vidyapeeth, Vadodara, Gujarat, India

<sup>2</sup>Narayana Nethralaya, Bengaluru, Karnataka, India



## ARTICLE INFO

## Article history:

Received 08-01-2020

Accepted 13-01-2020

Available online 17-03-2020

## Keywords:

OCT

Diabetics

HbA1c

Phacoemulsification

SICS

## ABSTRACT

**Purpose:** To study the relationship between HbA1c and macular thickness using Optical coherence tomography (OCT) in phacoemulsification and SICS.

**Materials and Methods:** Retrospective study where 100 eyes of type 2 Diabetes mellitus patients with mild to moderate Non-Proliferative Diabetic Retinopathy (NPDR) were included. 50 PATIENTS underwent uncomplicated phacoemulsification surgery AND REST 50 FOR SICS and were divided into 3 groups based on HbA1c levels – Group 1: <6.5%, Group 2: 6.5%–8% and group 3: >8%. Nine macular subfields as defined by Early Treatment of Diabetic Retinopathy study (ETDRS) were measured using OCT. The HbA1c level of each patient was measured and compared with the macular thickness as well as visual acuity.

**Result:** The macular thickness was found to be significantly higher postoperatively in SICS group ( $251.54 \pm 22.69 \mu\text{m}$ ) than the PHACO group ( $230.44 \pm 26.47 \mu\text{m}$ ) on post-operative day 7 and it further increased to ( $267.46 \pm 43.44 \mu\text{m}$ ) in SICS group as compared to phaco group ( $244.50 \pm 37.30 \mu\text{m}$ ) on postoperative 1 month in group C. CMT was highest if HbA1C levels were more than 8% as compared to other two groups on all post-operative day.

No significant difference was found in BCVA between both the groups on 1 month and 3 months post-operatively.

**Conclusion:** This study shows that cataract surgery increases the macular thickness and these increases are significantly higher in the SICS than in PHACO eyes on the POD 7, 1 month and 3 months after surgery, especially if HbA1c levels are more than 6.5%, which resolves to near normal levels in phaco group by POD 3 months. This indicates that phacoemulsification is more preferable surgery than SICS in adults with regard to postoperative increase in macular thickness. Also good control of HbA1c levels significantly decreases post-operative visual problems.

© 2020 Published by Innovative Publication. This is an open access article under the CC BY-NC-ND license (<https://creativecommons.org/licenses/by/4.0/>)

### 1. Introduction

Diabetes mellitus (DM) is well-known for causing multiple organ damage and life-threatening outcomes due to abnormal small vessel formation. Diabetic retinopathy (DR) is one of the manifestations of chronic diabetes causing leakage and neovascularization.<sup>1</sup> Since many decades, the diagnosis of DM is based on either fasting plasma glucose levels or 2 hours postprandial glucose levels. It was

only in 2010 that plasma glycosylated haemoglobin or HbA1c  $\geq 6.5\%$  was accepted by the American Diabetes Association as cut-off for DM and this modality helps to evaluate the glycosylated Hb over the past 3 months. It is now proved that HbA1c levels are better predictors of DR than any other routinely employed tests. DR can manifest in multiple forms as retinal haemorrhages, ischemia, neovascularization, and macular edema especially with poorly controlled HbA1c levels and long standing DM.<sup>2</sup> Out of these, macular edema is the most important predictor of poor visual outcome in diabetics, particularly

\* Corresponding author.

E-mail address: [avanisoni007@gmail.com](mailto:avanisoni007@gmail.com) (R. Sethia).

after cataract surgery.<sup>3</sup> It shows a higher incidence of macular edema (DME) which can either be ascribed to new vessel formation or immediate post-operative inflammation.<sup>4</sup> Optical coherence tomography (OCT) is a easy, quick, non-invasive tool that is immensely useful to an ophthalmologist to evaluate neovascularisation and assess the status of the macula. The central macular thickness (CMT) or foveal thickness is used to measure macular edema in DR and DME being the most common cause for sub-optimal visual outcome after routinely performed lens surgeries.<sup>5</sup> This research focuses on the influence of HbA1c levels on foveal thickness pre and post uncomplicated phacoemulsification and SICS surgeries.

## 2. Materials and Methods

This was a retrospective study conducted in the Ophthalmology department of Dhiraj Hospital, Vadodara. A total of 100 patients with type 2 DM were enrolled with us, out of which 50 patients underwent uncomplicated phacoemulsification with acrylic hydrophilic foldable IOL implantation and rest 50 underwent uncomplicated SICS with rigid PMMA IOL implantation. All the surgeries were performed by a single surgeon with uniform pre and postoperative protocol. All the participants gave informed consent before the study. The study also adhered to the tenets of the Declaration of Helsinki. The study was reviewed and approved by the institutional Ethics Committee of our hospital.

Patients known to have type II diabetes with mild to moderate Non-Proliferative Diabetic Retinopathy (NPDR), without pre-existing macular edema (on OCT, macular thickness of <280 microns) and co-existing senile cataract with nuclear sclerosis grade II to IV were included in our study. None had a history of the previous laser or intravitreal injections. The patients were subdivided into 3 groups based on their HbA1c levels as follows: Group 1 - HbA1c <6.5 %, Group 2-6.5 to 8% and Group 3 : >8%. The fasting blood sugar levels (FBS) and postprandial blood sugar (PPBS) levels were also measured pre and post-operatively in all patients who were already on diabetic treatment.

A complete ophthalmic workup including visual assessment using Snellen's chart (best corrected visual acuity) which was then converted to LogMAR for analysis, slit-lamp examination and tonometry were also done. The cataract grading was based on the LOCS III classification. Diabetic retinopathy evaluation was done by viewing dilated posterior segment, both pre and postoperatively on day 1, day 7, 1 month and 3 months. Optical Coherence Tomography (Topcon 3D OCT 1000) was also done preoperatively & postoperatively to measure foveal thickness by ETDRS grid. Three-dimensional macular thickness map analysis program was used to measure retinal thickness values in the fovea, parafoveal and perifoveal areas. Parafoveal areas were defined as the area between central 1-mm circle and the surrounding circle with 3-mm

diameter (i.e. area between 1- and 3- mm diameters) in four equal quadrants (i.e. superior, inferior, temporal, and nasal), while perifoveal areas were defined as the area between parafoveal and surrounding circle of 2 mm width. OCT analysis of each map was done to find cystic spaces or diffuse retinal thickening.

Group 1- Phacoemulsification through a standard 2.8 mm of limbal incision was done and foldable PCIOL was implanted in 50 eyes. We used Catarhex easy machine by Oertli for phacoemulsification. The average phaco power was between 50%-60% and absolute phaco time was  $15.9 \pm 7$  seconds while the entire procedure took  $14.5 \pm 5.5$  minutes.

Group 2- Manual SICS was done through a 5.5 to 6.5 mm incision with sclerocorneal tunnel and PMMA PCIOL was implanted in 50 eyes. The average SICS time was  $12.7 \pm 6.5$  minutes.

All the surgeries were uneventful and same post-operative medications were used in both the groups after surgery. (steroid-antibiotic combination eyedrops were used 4 times a day for one week followed by 3,2,1 weekly tapering in operated eye).

### 2.1. Statistical analysis

All the results are expressed as the number, percentage and mean  $\pm$  standard deviation (SD). Average Central Macular Thickness (CMT) between the two groups (phaco and SICS) was calculated and tabulated. Data was statistically analysed using Student's t-test. P-value <0.05 was considered as significant level. SPSS 2.0 was used for post hoc statistical analysis.

## 3. Results

Our study included 100 eyes of 100 patients, 50 underwent SICS and 50 patients underwent phacoemulsification procedure. Out of them, 33 patients belonged to group 1, 34 belonged to group 2 and 33 belonged to group 3 (Table 1). Intergroup variation in preoperative macular thickness was found to be statistically insignificant between SICS and PHACO groups.

A higher value of foveal thickness was observed in the SICS group than PHACO group during follow up. The highest and significant difference in macular thickness was found in group C on day 7 ( $251.54 \pm 22.68 \mu\text{m}$ ,  $p = 0.015$ ), 1 month ( $267.46 \pm 43.44 \mu\text{m}$ ,  $p = 0.031$ ) and 3 months ( $260.75 \pm 48.44 \mu\text{m}$ ,  $p = 0.002$ ) postoperatively in SICS patients. The foveal thickness resolved to near normal in the group A, but group B and C respectively showed a significant ( $p = 0.005$ ) difference during the final follow up on 3 months follow up, with a value of  $240.72 \pm 65.81 \mu\text{m}$  and  $237.19 \pm 40.70 \mu\text{m}$  in group B and C for PHACO patients and a  $251.50 \pm 59.36 \mu\text{m}$  and  $260.75 \pm 48.44 \mu\text{m}$  in SICS. (Table ??).

**Table 1:** Demographics and Preoperative information of all subjects

Parameters		Group 1 (<6.5)	Group 2 (6.5 – 8)	Group 3 (>8)	P
BCVA	Phaco	0.75±0.420	0.82±0.34	0.84±0.39	0.002
(LogMAR)	Sics	0.83±0.753	0.73±0.23	0.93±0.77	0.048
Age (year)	Phaco	55.06±9.77	54.13±4.23	62.67±8.33	NS
	Sics	57.39±10.54	60.56±6.44	68.93±11.35	NS
Gender	Phaco	7/9	8/9	8/9	NS
(Male/Female)	Sics	8/9	9/8	10/6	NS
CMTµm (±SD)(	Phaco	193.00±31.11µ	220.50±49.32µ	225.19±23.77µ	0.554
Preop)	Sics	188.00±35.76	232.43±41.68	235.98±25.45	0.498
HbA1c	Phaco	4.92±1.58	7.41±1.45	9.84±1.23	0.001
(mean±SD)	Sics	5.03±1.88	7.73±1.23	9.43±1.08	0.028

Thus, glycemic index plays an important role in predicting the macular thickness post-operatively especially in patients undergoing SICS while phaco group showed return of macular thickness to baseline by 3 months. (Table 2).

There was no statistically notable difference in pre and postoperative BCVA for all three groups. On post-operative 3 month, BCVA was comparable between SICS and phaco patients ( $p=0.322$ ,  $p=0.441$ ,  $p=0.284$  respectively) and there appears to be no association between the best corrected visual acuity (BCVA) and different levels of HbA1c. (Table 3)

#### 4. Discussion

Most of the cataract surgeries are associated with post-operative inflammation due to disruption of the blood-retina barrier (BRB) which leads to increased capillary permeability from the perifoveal network and fluid accumulation within retina, both intra and extracellular. One of the oldest and most commonly performed cataract procedure-Small Incision Cataract Surgery (SICS) has a larger incision, higher chances of damage to iris, and increased intra-operative tissue manipulation thereby, higher chances of inflammation. A newer modality of treatment-Phacoemulsification is a closed chamber surgery, causes lesser damage to ocular structures and anterior chamber reaction when done well. However, there is no evidence as to the significance of HbA1c control on the macular thickness of diabetic patients following cataract surgery.

Rostos et al in their review study suggested that when diabetic patients undergo cataract surgery, it might accelerate pre-existing diabetic macular oedema leading to poor visual outcome.<sup>6,7</sup> Some other researchers have also suggested that even in the absence of pre-existing DME, diabetic patients tend to have a higher propensity of developing DME after uncomplicated cataract surgery.<sup>8</sup>

Analysis done over the years between PHACO and SICS procedures showed that the macular thickness was higher

in SICS group. Many authors showed significant difference in macular thickness between PHACO and SICS group on 3<sup>rd</sup> day, 7<sup>th</sup> day, 3<sup>rd</sup> month and 6 months post-operative follow ups.<sup>9</sup> A study done by Dr. Indranil Roy et al on total 224 patients who were randomised to two groups- phaco and SICS, found mean central foveal thickness in SICS group was more than that of phaco group on post-op 1<sup>st</sup>, 7<sup>th</sup>, 42<sup>nd</sup> and 180<sup>th</sup> day. On day 180, mean central foveal thickness in SICS group was significantly ( $p=0.032$ ) more than phaco group.<sup>10</sup> Another study conducted by Dr. Dimpay et al on 100 eyes undergoing manual SICS showed that macular thickness was comparable preop and day 1 postop, while CMT increased in all patients at 4 weeks and 8 weeks and returned to near baseline values in most of the patients by 12 weeks.<sup>11</sup>

CME is the accepted as one of the frequent causes for suboptimal visual outcome after cataract surgeries and constitutes the most common cause of un predicted vision loss after many ocular procedures according to a research by Ray and D 'Amico et al in 2002.<sup>5</sup> Loewenstein and Zur et al (2010) reported a rate of clinical CME as 0.1-2.35% following modern cataract extraction procedures.<sup>12</sup>

Our study found a significant increase in CMT in SICS group as compared to phacoemulsification on postoperative day 7( $p=0.015$ ), 1 month ( $p=0.031$ ) and 3 months ( $p=0.002$ ) in group C. An increase in macular thickness was also noted in group B( $p=0.043$ ) on POD 7 which returned to near normal values by 1 month and showed no significant difference ( $p= 0.427$ ). Also group A showed no significant change in CMT on all post-operative days due to their well-controlled sugar levels, and only a non-significant difference was noted between SICS and phaco groups on POD 7 and 1 month. This indicated a strong correlation between poorly controlled HbA1c levels, causing significant visual morbidity postoperatively.

A similar correlation of HbA1c and postoperative macular edema in eyes with diabetic retinopathy was noted after phacoemulsification and SICS for as long as 12 months.<sup>13</sup> Progression of DR can be slowed down with judicious use of medications for controlling blood glucose

**Table 2:** Comparison of foveal thickness in each group pre and postop

HbA1c	Group Code		Mean	SD	p value	
<6.5 (N=16)	Baseline	Phaco	193.00	31.113	P = 0.422	
		Sics	201.50	28.515		
	POD 1	Phaco	210.00	49.497	P = 0.126	
		Sics	221.73	35.465		
	POD 7	Phaco	205.50	30.406	P = 0.056	
		Sics	219.00	39.465		
	POD 1 MONTH	Phaco	212.50	19.092	P = 0.040	
		Sics	226.00	16.433		
	POD 3 MONTHS	Phaco	195.00	33.941	P = 0.067	
		Sics	211.00	37.476		
	6.5 – 8 (N=18)	Baseline	Phaco	220.50	49.320	P = 0.353
			Sics	232.60	44.213	
POD 1		Phaco	240.39	57.998	P = 0.027	
		Sics	252.86	53.826		
POD 7		Phaco	243.83	51.903	P = 0.043	
		Sics	257.86	58.623		
POD 1 MONTH		Phaco	260.83	72.989	P = 0.427	
		Sics	264.65	66.167		
POD 3 MONTHS		Phaco	240.72	65.806	P = 0.028	
		Sics	251.50	59.367		
>8 (N=16)		Baseline	Phaco	225.19	23.772	P = 0.546
			Sics	223.64	27.578	
	POD 1	Phaco	226.13	28.714	P = 0.044	
		Sics	238.63	24.578		
	POD 7	Phaco	230.44	26.470	P = 0.002	
		Sics	251.54	22.687		
	POD 1 MONTH	Phaco	244.50	37.299	P = 0.003	
		Sics	267.46	43.443		
	POD 3 MONTHS	Phaco	237.19	40.696	P = 0.002	
		Sics	260.75	48.443		

levels and hyperlipidaemia according to the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study.<sup>14</sup> The Wisconsin Epidemiology Study of Diabetic Retinopathy (WESDR)<sup>15</sup> showed that poorly controlled HbA1c levels with higher fluctuations in blood glucose levels increased the incidence of DM E over a 10-year period (Klein et al. 1995). The Diabetes Control and Complication trial (DCCT)<sup>16</sup> and the UK Prospective Diabetic Study (UKPDS),<sup>17</sup> both of which were prospective randomized studies, showed that intensive glycaemic control and reduction of HbA1c levels are associated with a decrease in the rates of development as well as progression of diabetic retinopathy (DR) and DM E. OCT was utilized for more precise qualitative and quantitative assessment of macular thickness pre- and postoperatively.

In our study, the visual acuity did not deteriorate even if the macular thickness increased at 1 month postoperatively because removal of cataract caused significant clarity in visual axis of patient. Good visual acuity persisted even at 3 months postoperatively in both SICS and phaco group. According to Eriksson et al, changes in macula

occurring post-operatively is only transient in the short-term (6 weeks), even if patient has DR, and final visual outcome is non-inferior.<sup>14</sup> Therefore, diabetic patients may not show significant difference from the nondiabetic patients when we evaluate the short-term post-cataract surgery visual recovery. A reduction of HbA1c levels from 7.9% to 7.0% in type 2 diabetes resulted in reduction in the frequency of laser treatments needed.<sup>17</sup> In type 1 patients, a reduction of HbA1c values from 9.1% to 7.1% and improved blood glucose control reduced the risk of developing DR by 76% within 6.5 years, the risk of DR progression by 54%, and the risk of developing proliferative diabetic retinopathy (PDR) by 47%.<sup>18</sup> Therefore, an optimal level of less than or equal to 7% HbA1c levels should be aimed for an individual patient, from an ophthalmologist's point of view.<sup>19</sup> DCCT mentions the risk of developing CSME to be 23% for those patients who are on long term insulin treatments. The incidence of pseudopapillary cystoid macular edema ranges from 1%–30% depending on the risk factors defined for an individual, but the incidence remains on a higher side for diabetics. Unsal et al<sup>20</sup> observed that the mean

**Table 3:** Comparison of BCVA in each group

HbA1c	Group Code		Mean LogMAR	SD	p value	
<6.5 (N=16)	Baseline	Phaco	0.75	0.420	P = 0.089	
		Sics	0.67	0.120		
	POD 1	Phaco	0.22	0.140	P = 0.438	
		Sics	0.27	0.180		
	POD 7	Phaco	0.15	0.100	P = 0.485	
		Sics	0.18	0.060		
	POD 1 MONTH	Phaco	0.12	0.800	P = 0.067	
		Sics	0.18	0.140		
	POD 3 MONTHS	Phaco	0.10	0.008	P = 0.322	
		Sics	0.16	0.160		
6.5 – 8 (N=18)	Baseline	Phaco	0.82	0.340	P = 0.497	
		Sics	0.80	0.360		
	POD 1	Phaco	0.23	0.170	P = 0.362	
		Sics	0.20	0.070		
	POD 7	Phaco	0.19	0.110	P = 0.495	
		Sics	0.16	0.270		
	POD 1 MONTH	Phaco	0.1	0.090	P = 0.442	
		Sics	0.13	0.110		
	POD 3 MONTHS	Phaco	0.06	0.080	P = 0.441	
		Sics	0.09	0.060		
	>8 (N=16)	Baseline	Phaco	0.84	0.390	P = 0.262
			Sics	0.76	0.040	
POD 1		Phaco	0.21	0.140	P = 0.354	
		Sics	0.16	0.160		
POD 7		Phaco	0.19	0.100	P = 0.120	
		Sics	0.14	0.090		
POD 1 MONTH	Phaco	0.11	0.060	P = 0.234		
	Sics	0.09	0.040			
POD 3 MONTHS	Phaco	0.09	0.020	P = 0.284		
	Sics	0.08	0.030			

CMT (371  $\mu\text{m}$ ) in eyes with DME was significantly higher than the eyes with PDR (256  $\mu\text{m}$ ) and Non-Proliferative Diabetic Retinopathy (NPDR) (253  $\mu\text{m}$ ). Another study in contrast to our research states that no correlation exists between HbA1c levels and CMT in patients undergoing phacoemulsification.<sup>21</sup> The limitations of this study include shorter duration of follow-up (3 months), small sample size and duration of diabetes.

## 5. Conclusion

In this study, we found a correlation between HbA1c levels and macular thickness in diabetics undergoing phacoemulsification and SICS. A large number of patients undergoing SICS and belonging to group C showed a significant increase in central foveal thickness, beginning from 1<sup>st</sup> postoperative day till 3 months, but phacoemulsification group showed only slight increase in foveal thickness on postoperative 1 month which returned to near baseline levels by 3 months post-operatively. This indicates phacoemulsification procedure as an excellent choice for cataract removal in diabetics, thus avoiding unwanted complications. However, HbA1c levels had no correlation

with the final outcome in BCVA in our study.

## 6. Source of Funding

None.

## 7. Conflict of Interest

None.

## References

- Cade WT. Diabetes-Related Microvascular and Macrovascular Diseases in the Physical Therapy Setting. *Phys Ther*. 2008;88(11):1322–1335.
- Benarous R, Sasongko MB, Qureshi S, Fenwick E, Dirani M, et al. Differential Association of Serum Lipids with Diabetic Retinopathy and Diabetic Macular Edema. *Invest Ophthalmol Vis Sci*. 2011;52(10):7464–7464.
- Criel M, Jonckheere S, Langlois M. Evaluation of Three Hemoglobin A1c Point-of-Care Instruments. *Clin Lab*. 2016;62:285–291.
- International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. *Diabetes Care*. 2009;32(7):1327–1334.
- Ray S, Amico D, J D. Pseudophakic cystoid macular edema. *Semin Ophthalmol*. 2002;17(3-4):167–180.
- Rostos TG, Moschos MM. Cystoid macular edema. *Clin Ophthalmol*. 2008;2(4):919–930.

7. Sood S, Narang S. Evaluation of macular thickness after uncomplicated phacoemulsification using OCT. *AIOC*. 2009;.
8. Fernandez-Blanco TC, Ruiz-Moreno O, Ferrer-Novella E. Pseudophakic cystoid macular edema assessment with OCT. *Arch Soc Esp Ophthalmol*. 2006;81(3):147–154.
9. Mandal P, Srivastava SR. Macular Thickness, OCT, Phacoemulsification, SICS. Comparative evaluation of macular thickness after phacoemulsification vs manual sics by ocular coherence tomography in diabetic patients. 2016; Available from: <https://jebmh.com/latest-articles/95409>.
10. Roy I, Biswas PN, Ghosh S. Prospective randomized comparative study of macular thickness by OCT following phacoemulsification & manual SICS. In: *AIOC* ; 2009, . .
11. Gothwal D, Grover T, Grover A. Incidence of CME following manual SICS using OCT. In: *AIOC* ; 2009, . .
12. Loewenstein A, Zur D. Postsurgical cystoid macular edema. *Dev Ophthalmol*. 2010;47:148–159.
13. Hayashi K, Igarashi C, Hirata A, Hayashi H. Changes in diabetic macular oedema after phacoemulsification surgery. *Eye (Lond)*. 2009;23:389–396.
14. Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. *N Engl J Med*. 2010;363(3):233–244.
15. Klein R, Klein BEK, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XV. *Ophthalmol*. 1995;102(1):7–16.
16. Lachin JM, Genuth S, Cleary P, Davis MD, Nathan DM. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive insulin therapy, by The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. *N Engl J Med*. 2000;342:381–389.
17. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet*. 1998;352:837–853.
18. Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. *N Engl J Med*. 1993;329:977–986.
19. Nentwich MM. Diabetic retinopathy - ocular complications of diabetes mellitus. *World J Diabetes*. 2015;6(3):489–499.
20. Unsal E, Eltutar K, Zirtiloglu S, Dincer N, Erkul SO, Gungel H. Choroidal thickness in patients with diabetic retinopathy. *Clin Ophthalmol*. 2014;8:637–642.
21. Sethia R, Mehta PK, Kothari R, Desai V, Soni A. A Correlation of Glycemic Index and Macular Thickness After Phacoemulsification in Diabetics. *Sci J Delhi Ophthalmol Soc*. 2019;29(4):39–43.

### Author biography

**Avani Soni** Resident

**Rajni Sethia** Associate Professor

**Parin Mehta** Glaucoma Fellow

**Zeel Patel** Resident

**Cite this article:** Soni A, Sethia R, Mehta P, Patel Z, Vyas A. To study correlation of HbA1c and macular thickness changes in diabetic patients after phacoemulsification and small incision cataract surgery (SICS). *Indian J Clin Exp Ophthalmol* 2020;6(1):108–113.